LONDON--(BUSINESS WIRE)--
The market for epilepsy, a brain disorder marked by spontaneously occurring and recurrent seizures, is primarily driven by the sales of anti-epileptic drugs (AEDs) aimed at reducing these seizures. At present, the worldwide AED market is dominated by UCBs Keppra and GlaxoSmithKlines Lamictal, with both drugs forming the mainstay of epilepsy treatment in the nine markets and likely to keep on enjoying remarkable market share up to 2022.
The AED market landscape, however, is expected to be dominated by newer generation drugs, such as Vimpat (lacosamide) UCBs drug that is currently indicated as an adjunctive therapy for partial-onset seizures in individuals over the age of 17. Unlike other sodium channel-targeting AEDs, Lacosamide is the only drug that reduces voltage-gated sodium channel availability by selective enhancement of slow inactivation, but without apparent interaction with fast-inactivation gating.
New market research report Vimpat (Epilepsy) - Forecast and Market Analysis to 2022 created by GlobalData offers a comprehensive guide to the global epilepsy drugs market, with a particular focus on newer generation Vimpat (lacosamide).
The study provides an in-depth overview of this neurologic disease covering epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines, besides providing an understanding of the changing competitive landscape. The research proceeds with giving detailed information on Vimpat, including the product description, safety and efficacy profiles as well as a SWOT analysis. The research work is enriched with sales forecasts for Vimpat for the top 8 countries the US, France, Germany, Italy, Spain, the UK, Japan and India, from 2012 up to 2022.
Report Details:
Title: Vimpat (Epilepsy) - Forecast and Market Analysis to 2022 Published: February, 2013 Pages: 51 Price: US$ 6,995.00
More Epilepsy Drugs Market Research Reports by GlobalData Include:
More new market research reports by GlobalData can be found at http://marketpublishers.com/members/global_data/info.html
See the article here:
Vimpat Therapeutic Role in Epilepsy Studied in New In-Demand GlobalData Report Available at MarketPublishers.com